Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC)
protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural …

Undruggable proteins are a class of proteins that are often characterized by large, complex
structures or functions that are difficult to interfere with using conventional drug design …

Targeted therapies in cancer treatment can improve in vivo efficacy and reduce adverse
effects by altering the tissue exposure of specific biomolecules. However, there are still large …

When small proteins such as cytokines bind to their associated receptors on the plasma
membrane, they can activate multiple internal signaling cascades allowing information from …

The protein cereblon (CRBN) is a substrate receptor of the cullin 4-really interesting new
gene (RING) E3 ubiquitin ligase complex CRL4 CRBN. Targeting CRBN mediates selective …

Targeted protein degradation (TPD) is a revolutionary approach to targeted therapy in
hematological malignancies that potentially circumvents many constraints of existing small …

Small-molecule drugs are effective and thus most widely used. However, their applications
are limited by their reliance on active high-affinity binding sites, restricting their target …

The ubiquitin-proteasome system is the crucial homeostatic mechanism responsible for the
degradation and turnover of proteins. As such, alterations at this level are often associated …

Neurodegenerative diseases (NDD) are characterized by the gradual deterioration of
neuronal function and integrity, resulting in an overall decline in brain function. The existing …

Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive
lymphoma. Recent advances in immunotherapy such as chimeric antigen receptor T-cell …